Kiltearn Partners Llp Lifted Viacom New (VIAB) Position by $37.57 Million; Adma Biologics (ADMA) Shares Declined While Iguana Healthcare Management Has Increased by $1.25 Million Its Holding

February 23, 2018 - By Darrin Black

Stuart Weisbrod increased its stake in Adma Biologics Inc (ADMA) by 276.67% based on its latest 2017Q3 regulatory filing with the SEC. Iguana Healthcare Management Llc bought 415,000 shares as the company’s stock declined 24.29% while stock markets rallied. The hedge fund run by Stuart Weisbrod held 565,000 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $1.74 million, up from 150,000 at the end of the previous reported quarter. Iguana Healthcare Management Llc who had been investing in Adma Biologics Inc for a number of months, seems to be bullish on the $170.84 million market cap company. The stock decreased 1.31% or $0.0501 during the last trading session, reaching $3.7699. About 3,495 shares traded. ADMA Biologics, Inc. (NASDAQ:ADMA) has declined 37.56% since February 23, 2017 and is downtrending. It has underperformed by 54.26% the S&P500.

Kiltearn Partners Llp increased its stake in Viacom Inc New (VIAB) by 114.35% based on its latest 2017Q3 regulatory filing with the SEC. Kiltearn Partners Llp bought 1.39M shares as the company’s stock declined 19.98% while stock markets rallied. The institutional investor held 2.61M shares of the television services company at the end of 2017Q3, valued at $72.61M, up from 1.22M at the end of the previous reported quarter. Kiltearn Partners Llp who had been investing in Viacom Inc New for a number of months, seems to be bullish on the $13.65 billion market cap company. The stock increased 1.06% or $0.3487 during the last trading session, reaching $33.2787. About 444,431 shares traded. Viacom, Inc. (NASDAQ:VIAB) has declined 8.36% since February 23, 2017 and is downtrending. It has underperformed by 25.06% the S&P500.

Kiltearn Partners Llp, which manages about $3.16 billion and $3.42 billion US Long portfolio, decreased its stake in Citigroup Inc (NYSE:C) by 114,400 shares to 4.42M shares, valued at $321.82 million in 2017Q3, according to the filing. It also reduced its holding in State Str Corp (NYSE:STT) by 169,919 shares in the quarter, leaving it with 537,895 shares, and cut its stake in Borgwarner Inc (NYSE:BWA).

Among 39 analysts covering Viacom Inc. (NASDAQ:VIAB), 12 have Buy rating, 2 Sell and 25 Hold. Therefore 31% are positive. Viacom Inc. had 131 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by UBS on Friday, November 17. Wunderlich maintained Viacom, Inc. (NASDAQ:VIAB) on Wednesday, September 21 with “Buy” rating. The stock has “Hold” rating by Needham on Tuesday, September 12. The firm has “Hold” rating by Topeka Capital Markets given on Friday, August 7. The stock has “Sell” rating by RBC Capital Markets on Tuesday, August 8. The company was downgraded on Tuesday, November 15 by FBR Capital. The rating was maintained by Needham with “Hold” on Friday, November 3. The firm earned “Equal-Weight” rating on Friday, October 20 by Barclays Capital. On Monday, October 9 the stock rating was downgraded by Citigroup to “Sell”. Citigroup maintained Viacom, Inc. (NASDAQ:VIAB) rating on Wednesday, May 18. Citigroup has “Neutral” rating and $41 target.

Iguana Healthcare Management Llc, which manages about $139.00M and $183.53M US Long portfolio, decreased its stake in Merus N V by 35,000 shares to 140,000 shares, valued at $2.78 million in 2017Q3, according to the filing. It also reduced its holding in Zogenix Inc by 65,000 shares in the quarter, leaving it with 20,000 shares, and cut its stake in Merck & Co Inc (NYSE:MRK).

Among 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ADMA Biologics had 8 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Thursday, September 17. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) earned “Buy” rating by Maxim Group on Wednesday, June 28. The firm has “Buy” rating by Maxim Group given on Wednesday, June 7. Raymond James initiated ADMA Biologics, Inc. (NASDAQ:ADMA) on Wednesday, September 9 with “Strong Buy” rating. The firm earned “Outperform” rating on Tuesday, November 14 by Raymond James. Raymond James downgraded the shares of ADMA in report on Monday, August 1 to “Market Perform” rating. As per Monday, January 23, the company rating was upgraded by Maxim Group. The company was downgraded on Monday, August 1 by Maxim Group.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>